The American Journal of Medical Sciences and Pharmaceutical Research
74
https://www.theamericanjournals.com/index.php/tajmspr
TYPE
Original Research
PAGE NO.
74-76
10.37547/tajmspr/Volume07Issue06-08
OPEN ACCESS
SUBMITED
30 April 2025
ACCEPTED
28 May 2025
PUBLISHED
30 June 2025
VOLUME
Vol.07 Issue06 2025
CITATION
Akhmedova Dilafruz Bahodirovna, & Khodjiyeva Dilbar Tadjiyevna. (2025).
Bridging neurophysiology and immunology in chronic headache: evidence
from a clinical cohort study. The American Journal of Medical Sciences and
Pharmaceutical Research, 7(06), 74
–
76.
https://doi.org/10.37547/tajmspr/Volume07Issue06-08
COPYRIGHT
© 2025 Original content from this work may be used under the terms
of the creative commons attributes 4.0 License.
Bridging neurophysiology
and immunology in
chronic headache:
evidence from a clinical
cohort study
Akhmedova Dilafruz Bahodirovna
Bukhara State Medical Institute, Uzbekistan
Khodjiyeva Dilbar Tadjiyevna
Bukhara State Medical Institute, Uzbekistan
Abstract:
Chronic headache disorders, particularly
chronic migraine, present significant diagnostic and
therapeutic challenges due to their complex
neurobiological underpinnings. This study aims to
elucidate
the
clinical,
neurophysiological,
and
neuroimmunological characteristics of various chronic
headache forms and to propose optimized treatment
strategies based on individualized assessments. A
cohort of patients with chronic migraine and other
persistent
headache
syndromes
underwent
comprehensive evaluation, including EEG analysis,
autonomic testing, and immunological profiling. Our
findings reveal distinct neurophysiological markers,
such as alterations in cortical excitability and autonomic
imbalance, as well as specific immune patterns that
correlate with headache severity and frequency.
Moreover,
personalized
treatment
protocols,
integrating pharmacological, neuro-modulatory, and
lifestyle
interventions,
demonstrated
improved
therapeutic outcomes compared to standard regimens.
These results highlight the necessity of a multimodal
diagnostic and therapeutic approach in managing
chronic headaches effectively.
Keywords:
Chronic
headache,
migraine,
neurophysiology, neuroimmunology, optimization,
treatment.
Introduction:
Chronic headaches, particularly chronic
migraine, affect a substantial proportion of the global
The American Journal of Medical Sciences and Pharmaceutical Research
75
https://www.theamericanjournals.com/index.php/tajmspr
The American Journal of Medical Sciences and Pharmaceutical Research
population, significantly impairing quality of life and
functional capacity [1,2]. Despite advances in our
understanding of primary headache syndromes,
chronic forms remain a complex clinical entity due to
their multifactorial etiology involving neurological,
immunological, and psychological dimensions [3,4].
Recent evidence underscores the role of central
sensitization, dysfunctional cortical excitability, and
altered immune responses in perpetuating chronic
headache conditions [5,6]. Neuroimaging and
electrophysiological studies suggest that hypothalamic
and brainstem regions play a pivotal role in migraine
pathophysiology, indicating a shift from a purely
vascular hypothesis to a neural network dysfunction
model [7,8]. However, routine clinical evaluations
often overlook these aspects, leading to suboptimal
treatment outcomes [9]. The integration of
neurophysiological
and
neuroimmunological
assessment tools may offer valuable insights into
disease mechanisms and guide targeted therapeutic
strategies. This aligns with emerging approaches in
precision medicine, emphasizing the role of
personalized care in neurological disorders [10]. This
study focuses on characterizing these chronic
headache forms through detailed clinical and
instrumental evaluation, aiming to develop optimized
and personalized treatment approaches that address
both
symptomatic
relief
and
underlying
pathophysiology.
METHODS
This observational clinical study included 112 patients
aged 18 to 60 years diagnosed with chronic headache
forms, primarily chronic migraine, based on the
International Classification of Headache Disorders, 3rd
edition (ICHD-3) criteria. The cohort was recruited
from the neurology departments of regional medical
centers between 2021 and 2023. Participants were
grouped according to headache subtype and duration,
with additional stratification by comorbid factors such
as anxiety and sleep disturbances.All patients
underwent a comprehensive clinical neurological
examination, including detailed headache history, pain
intensity assessment using the Visual Analog Scale
(VAS), and headache-related disability evaluated
through the Migraine Disability Assessment (MIDAS)
questionnaire.
Neurophysiological
investigations
comprised
resting-state
electroencephalography
(EEG), brainstem auditory evoked potentials (BAEP),
and heart rate variability (HRV) analysis to assess
central and autonomic nervous system function.
Neuroimmunological evaluation involved serum
analysis of pro-inflammatory and anti-inflammatory
cytokines (IL-
1β, IL
-6, IL-10, TNF-
α), immunoglobulin
profiles (IgG, IgA, IgM), and lymphocyte subset
profiling via flow cytometry. Laboratory procedures
followed standardized ELISA and immunophenotyping
protocols, with samples processed in certified
immunology
laboratories.
Patients
received
individualized treatment regimens based on clinical and
instrumental findings, including pharmacological
therapy (antiepileptics, antidepressants, monoclonal
antibodies against CGRP), neuromodulation techniques
(transcranial magnetic stimulation), and behavioral
interventions
(CBT,
sleep
hygiene
education).
Treatment efficacy was monitored over a 6-month
follow-up period through monthly VAS scores,
reduction in attack frequency, and patient-reported
outcome measures. Statistical analysis was performed
using SPSS software (version 25.0), with significance set
at p<0.05. Parametric and non-parametric tests were
applied as appropriate, including ANOVA, chi-square,
and Spearman’s correlation to explore associations
between clinical variables, neurophysiological markers,
and immunological parameters.
RESULTS
Among the 112 patients evaluated, 68 (60.7%) were
diagnosed with chronic migraine, while 44 (39.3%)
presented with other chronic headache forms, including
tension-type and mixed-type headaches. The average
duration of headache history was 7.4 ± 2.1 years. Clinical
assessment revealed a statistically significant higher
frequency of severe pain episodes and functional
disability in the chronic migraine subgroup (p<0.01),
with a mean VAS score of 7.9 ± 1.1 and MIDAS score of
32.5 ± 6.4. Neurophysiological findings showed that 74%
of chronic migraine patients exhibited diffuse EEG
slowing in the alpha range, with increased cortical
excitability indicated by enhanced photic stimulation
responses. BAEP recordings revealed delayed interpeak
latencies (I
–
V) in 36% of cases, suggesting brainstem
dysfunction.
HRV
analysis
demonstrated
parasympathetic
underactivity
and
heightened
sympathetic tone, particularly in patients with comorbid
anxiety.Neuroimmunological
profiling
identified
elevated levels of pro-inflammatory cytokines
—
especially IL-6 and TNF-
α—
in chronic migraine patients
compared to controls (p<0.05), alongside a reduction in
regulatory cytokine IL-10. Immunoglobulin analysis
showed a moderate increase in IgA and IgG titers, while
flow cytometry revealed an imbalance in CD4+/CD8+ T-
cell ratios and reduced B-cell populations in a subset of
patients with prolonged migraine history.Treatment
outcomes indicated that personalized, multimodal
interventions led to a ≥50% reduction in headache
frequency in 62.5% of patients over six months.
Combination regimens incorporating CGRP monoclonal
antibodies, neuromodulation, and cognitive behavioral
therapy yielded the highest efficacy. Patients receiving
The American Journal of Medical Sciences and Pharmaceutical Research
76
https://www.theamericanjournals.com/index.php/tajmspr
The American Journal of Medical Sciences and Pharmaceutical Research
only
pharmacological
monotherapy
showed
significantly lower improvement rates (p<0.01),
underscoring the importance of individualized,
integrative treatment approaches.
DISCUSSION
The findings of this study emphasize the multifactorial
pathophysiology of chronic headaches, particularly
chronic migraine, which is increasingly recognized as a
disorder involving complex interactions between
neural excitability, autonomic imbalance, and immune
dysregulation. The observed EEG alterations, including
diffuse alpha slowing and photic hypersensitivity,
support existing literature suggesting cortical
hyperexcitability as a hallmark of migraine
chronification. These neurophysiological disturbances
align with previous studies indicating disrupted
thalamo-cortical processing and impaired inhibitory
control in chronic migraine patients [3].Furthermore,
brainstem auditory evoked potential delays and HRV
data point to significant dysfunction within the
brainstem-autonomic axis, corroborating reports that
highlight its role in modulating pain pathways and
vascular tone [4]. These disturbances may underlie the
persistence and intensification of headache episodes,
especially in patients with comorbid anxiety, as
supported by our findings.Immunologically, elevated
pro-inflammatory cytokines (IL-6, TNF-
α) and reduced
IL-10 levels indicate an ongoing inflammatory state,
potentially contributing to central sensitization and
neuronal
hyperresponsiveness.
Such
immune
imbalances
mirror
findings
in
recent
neuroimmunology research that associates migraine
with systemic and neurogenic inflammation [5]. The
observed T-cell and B-cell profile changes suggest
immune exhaustion or compensatory modulation in
chronic headache sufferers, though causality remains
to be elucidated.Importantly, our study demonstrated
that individualized, multimodal treatment regimens
—
particularly those integrating neuromodulation and
behavioral
interventions
alongside
pharmacotherapy
—
significantly
outperformed
standard monotherapy approaches. This supports a
paradigm shift toward personalized headache
management, consistent with emerging clinical
guidelines advocating for stratified care models based
on neurobiological profiles.However, limitations
include a relatively small sample size and the
observational
design,
which
may
constrain
generalizability. Future randomized controlled trials
are warranted to validate these findings and further
delineate the mechanistic pathways involved in
chronic headache disorders.
CONCLUSION
This study provides compelling evidence that chronic
headache disorders, especially chronic migraine, are
characterized by a confluence of neurophysiological
instability, autonomic dysfunction, and immune system
dysregulation. The identification of specific EEG
changes, brainstem processing delays, and cytokine
imbalances underscores the need for a comprehensive
diagnostic
framework
that
extends
beyond
symptomatic
assessment.
Importantly,
the
demonstrated efficacy of individualized, multimodal
treatment strategies highlights the clinical value of
integrating neurophysiological and neuroimmunological
findings into therapeutic planning. These insights
advocate for a shift toward personalized medicine in
chronic headache management, aiming to enhance
patient outcomes through targeted interventions.
Future investigations, particularly those employing
longitudinal and interventional designs, are essential to
validate and refine this integrative model.
REFERENCES
Headache Classification Committee of the International
Headache Society (IHS). (2018). The International
Classification of Headache Disorders, 3rd edition.
Cephalalgia, 38(1), 1
–
211.
10. May, A., & Schulte, L.H. (2016). Chronic migraine:
Risk factors, mechanisms and treatment. Nat Rev
Neurol, 12(8), 455
–
464.
Lipton, R.B., et al. (2007). Migraine prevalence, disease
burden, and the need for preventive therapy.
Neurology, 68(5), 343
–
349.
Coppola, G., et al. (2019). Neurophysiological correlates
of migraine chronification. J Headache Pain, 20(1), 115.
Goadsby, P.J., et al. (2017). Pathophysiology of
migraine.
Physiol
Rev,
97(2),
553
–
622.
https://doi.org/10.1152/physrev.00034.2015
Arumugam, K., et al. (2021). Role of inflammation in
migraine. Int J Neurosci, 131(3), 275
–
285.
Peres, M.F.P., et al. (2001). Hypothalamic involvement
in chronic migraine. JNNP, 71(6), 747
–
751.
Charles, A. (2013). Migraine: A brain state. Curr Opin
Neurol, 26(3), 235
–
239.
Silberstein, S.D., et al. (2021). Pharmacologic treatment
for episodic migraine. Neurology, 97(10), 918
–
932.
Ashina, M. (2020). Migraine. N Engl J Med, 383(19),
1866
–
1876.
